

# Dennis Vriens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/364974/publications.pdf>

Version: 2024-02-01

51  
papers

1,144  
citations

535685

17  
h-index

445137

33  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacology of Radiotheranostics in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 260-274.	2.3	9
2	[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1970-1984.	3.3	22
3	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2174-2188.	3.3	19
4	FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3452-3469.	3.3	9
5	<sup>89</sup> Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1523-1530.	2.8	15
6	Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
7	Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2980-e2994.	1.8	14
8	Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?. <i>Diagnostics</i> , 2021, 11, 553.	1.3	1
9	The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis. <i>Diagnostics</i> , 2021, 11, 1296.	1.3	6
10	Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1527-1537.	3.3	17
11	Adding the temporal domain to PET radiomic features. <i>PLoS ONE</i> , 2020, 15, e0239438.	1.1	12
12	Considerations on bone volume normalization in quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1351-1352.	3.3	1
13	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 676-691.	0.4	5
14	Nuclear medicine radiomics in precision medicine: why we can't do without artificial intelligence. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 278-290.	0.4	9
15	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.4	4
16	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
17	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
18	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0

#	ARTICLE	IF	CITATIONS
19	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
20	18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. Skeletal Radiology, 2019, 48, 1735-1746.	1.2	18
21	Metabolic Subtyping of Pheochromocytoma and Paraganglioma by <sup>18</sup> F-FDG Pharmacokinetics Using Dynamic PET/CT Scanning. Journal of Nuclear Medicine, 2019, 60, 745-751.	2.8	21
22	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocrine Reviews, 2018, 39, 154-191.	8.9	45
23	Chronic temporomandibular joint pain: two cases of osteoid osteoma and a review of the literature. International Journal of Oral and Maxillofacial Surgery, 2017, 46, 1130-1137.	0.7	10
24	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic <sup>18</sup> F Fluorodeoxyglucose PET. Radiology, 2017, 283, 547-559.	3.6	16
25	PV-0372: Histology-specific quantitative mapping and targeting of glucose and glutamine metabolism in NSCLC. Radiotherapy and Oncology, 2017, 123, S200-S201.	0.3	0
26	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric <sup>18</sup> F-FDG PET Images in Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1033-1039.	2.8	31
27	EP-1851: Quantitative assessment of glucose metabolic rate within NSCLC histologies using dynamic <sup>18</sup> F-FDG PET. Radiotherapy and Oncology, 2016, 119, S871.	0.3	0
28	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. Endocrine, 2016, 54, 642-647.	1.1	8
29	PO-0919: Optimal respiratory gated FDG-PET for characterizing intra-tumour heterogeneity in lung cancer. Radiotherapy and Oncology, 2016, 119, S445.	0.3	0
30	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on <sup>18</sup> F-FDG PET Imaging of Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1692-1698.	2.8	67
31	Anakinra Injection Site Reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-493.	0.7	3
32	Semiquantitative <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. Journal of Nuclear Medicine, 2015, 56, 839-846.	2.8	30
33	Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A&gt;G Carriers. JIMD Reports, 2015, 24, 69-81.	0.7	39
34	Human Terrain System (United States): Critique. , 2015, , 392-399.		0
35	Serum FGF21 levels in adult m.3243A&gt;G carriers. Neurology, 2014, 83, 125-133.	1.5	33
36	The influence of SPECT reconstruction algorithms on image quality and diagnostic accuracy in phantom measurements and <sup>99m</sup> Tc-sestamibi parathyroid scintigraphy. Nuclear Medicine Communications, 2014, 35, 64-72.	0.5	9

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness of FDG-PET/CT for Cytologically Indeterminate Thyroid Nodules: A Decision Analytic Approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3263-3274.	1.8	47
38	Quantitative Assessment of Heterogeneity in Tumor Metabolism Using FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e725-e731.	0.4	35
39	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012, 12, 324-335.	1.2	17
40	Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET. <i>Clinical Colorectal Cancer</i> , 2011, 10, E1-E5.	1.0	16
41	F-18 FDG PET/CT as a Crucial Guide Toward Optimal Treatment Planning in a Case of Postirradiation Sarcoma 10 Years After Primary Bone Lymphoma of the Pelvis. <i>Clinical Nuclear Medicine</i> , 2011, 36, 565-567.	0.7	1
42	The role of [ <sup>18</sup> F]2-deoxy-2-fluoro-D-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy. <i>Cancer</i> , 2011, 117, 4582-4594.	2.0	79
43	Shortened Dynamic <sup>18</sup> F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1330.1-1330.	2.8	1
44	Hardware Failure. <i>Clinical Nuclear Medicine</i> , 2010, 35, 430-433.	0.7	1
45	Methodological considerations in quantification of oncological FDG PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1408-1425.	3.3	108
46	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2037-2047.	3.3	45
47	A Curve-Fitting Approach to Estimate the Arterial Plasma Input Function for the Assessment of Glucose Metabolic Rate and Response to Treatment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1933-1939.	2.8	68
48	Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1777-1784.	2.8	29
49	Monitoring and Predicting Response to Therapy with <sup>18</sup> F-FDG PET in Colorectal Cancer: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2009, 50, 43S-54S.	2.8	197
50	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 550-557.	0.5	16
51	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma. , 2008, , .		7